Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: A Korea-Japan collaborative study

Annals of Hematology

Volumn 93, Issue 8, 2014, Pages 1345-1351

  Kim, Ji Won ^a,b   Kim, Sung Won ^c   Tada, Kohei ^c   Fukuda, Takahiro ^c   Lee, Je Hwan ^d   Lee, Je Jung ^e   Kwon, Ji Hyun ^a,b   Bang, Soo Mee ^f   Kim, Inho ^a,b   Yoon, Sung Soo ^a,b   Lee, Jong Seok ^f   Park, Seonyang ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d Asan Medical Center   (South Korea)

^e Chonnam National University Research Institute of Medical Sciences   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Risk factor; Stem cell transplantation

Indexed keywords

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; JAPAN; KOREA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; THERAPY; TREATMENT OUTCOME;

ADULT; ALLOGRAFTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REOPERATION; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84904745181     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2045-9     Document Type: Article

References (26)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540-1545
2. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369(18):1681-1690. doi:10.1056/NEJMoa1301077
3. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350(13):1287-1295. doi:10.1056/NEJMoa031770 (Pubitemid 38375363)
4. Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ, Sierra J, Gandarillas M, Perez-Simon JA, Zuazu J, Lopez-Guillermo A, Sureda A, Carreras E, Garcia-Larana J, Marin J, Garcia JC, Fernandez De Sevilla A, Rifon J, Varela R, Jarque I, Albo C, Leon A, SanMiguel J, Conde E (2004) Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin 's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 15(10):1504-1509. doi:10.1093/annonc/mdh391
5. Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Frappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142-2148
6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B et al (1990) Graft-versus- leukemia reactions after bone marrow transplantation. Blood 75(3):555-562 (Pubitemid 20069191)
7. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, Buzyn A, Boogaerts MA, Luan JJ, Maury S, Milpied NJ, Jouet JP, Ossenkoppele GJ, Sureda A (2011) Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin 's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29(10):1342- 1348. doi:10.1200/JCO.2010.30.2596
8. Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S, Ciceri F, Fanin R, Rambaldi A, Falda M, Milone G, Guidi S, Martelli MF, Mazza P, Oneto R, Bosi A, Trapianto GI, di Midollo O (2012) Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 91(6):931-939. doi: 10.1007/s00277-011-1395-9
9. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin's disease staging classification. Cancer Res 31(11):1860-1861
10. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244
11. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579-586. doi: 10.1200/JCO.2006.09.2403 (Pubitemid 350002966)
12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6): 825-828
13. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69(2):204 -217
14. de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE (1997) Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 19(2):121-127. doi:10.1038/sj.bmt.1700614
15. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104(12):3797-3803. doi:10.1182/blood-2004-01-0231 (Pubitemid 39564460)
16. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104(13):3865-3871. doi:10.1182/blood-2004-03-1105 (Pubitemid 39620131)
17. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F, Agura E, Chauncey T, Maziarz RT, Maris M, Shizuru J, Bruno B, Bredeson C, Lange T, Yeager A, Sandmaier BM, Storb RF, Maloney DG (2008) Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 143(3):395-403. doi:10. 1111/j.1365-2141.2008.07365.x
18. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G, Schmitz N, Lymphoma Working Party of the European Group for B, Bone Marrow T (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100(13):4310-4316. doi:10.1182/blood-2001-11- 0107 (Pubitemid 35429668)
19. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF (2004) Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22(12):2419-2423. doi:10.1200/JCO.2004.09.092 (Pubitemid 41115399)
20. Peggs KS, Mackinnon S, Linch DC (2005) The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 128(2): 153-168. doi:10.1111/j.1365-2141.2004.05251.x
21. Schmitz N, Dreger P, Glass B, Sureda A (2007) Allogeneic transplantation in lymphoma: current status. Haematologica 92(11):1533-1548. doi:10.3324/haematol.11185 (Pubitemid 350144129)
22. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R (2008) Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111(1):446-452. doi:10.1182/blood-2007-07-098483
23. van Besien KW, de Lima M, Giralt SA, Moore DF Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE (1997) Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus- lymphoma effect. Bone Marrow Transplant 19(10):977-982. doi:10.1038/sj.bmt.1700781 (Pubitemid 27232173)
24. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH (2008) Clinical evidence of a graft-versuslymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19(11):1935-1940. doi:10.1093/annonc/mdn404
25. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9):3108-3114. doi:10.1182/blood-2002-02-0506 (Pubitemid 35217056)
26. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM (2003) Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 32(12):1159-1163. doi:10.1038/sj.bmt.1704290 (Pubitemid 38072329)